论文部分内容阅读
目的探讨沙利度胺联合VTD方案治疗多发性骨髓瘤(MM)的临床效果及不良反应。方法观察采用沙利度胺(T)、长春新碱(V)、吡喃阿霉素(T)和地塞米松(D)方案联合治疗25例初治性和13例复发难治性MM的效果和不良反应。结果初治MM 25例中15例完全缓解(CR),5例部分缓解(PR),5例进步(I)。复发难治MM 13例中6例CR,4例PR,3例无效。不良反应有乏力、嗜睡、腹胀、便秘及感染等,但均可耐受。结论T-VTD是治疗初治和复发难治MM效果好而又安全的方案。
Objective To investigate the clinical effects and adverse reactions of thalidomide combined with VTD in the treatment of multiple myeloma (MM). Methods 25 cases of newly diagnosed and 13 relapsed refractory MM were treated with thalidomide (T), vincristine (V), pirarubicin (T) and dexamethasone (D) Effects and adverse reactions. Results Among the 25 newly diagnosed MM patients, 15 were completely relieved (CR), 5 were partially relieved (PR) and 5 were progressive (I). Recurrence refractory MM 13 cases, 6 cases of CR, 4 cases of PR, 3 cases of ineffective. Adverse reactions are fatigue, drowsiness, bloating, constipation and infection, but can be tolerated. Conclusion T-VTD is a safe and effective treatment for MM with initial treatment and relapse-refractory MM.